Medsider: Learn from MedTech and HealthTech Experts: Recent Episodes
Scott Nelson
Learn from proven medtech and healthtech experts. That's our primary goal with Medsider. Through uncut interviews with the world's brightest thought leaders, you'll pick up on helpful insights, lessons learned, best practices, and much more.
In this episode of Medsider Radio, we pull back the curtain on Luke Fox, the visionary founder of NEXT Life Sciences. With an ambitious mission to democratize family planning, Luke and his team are on the brink of launching their flagship product, Plan A— a groundbreaking male contraceptive.
Before founding NEXT Life Sciences, Luke Fox was already a powerhouse entrepreneur in numerous highly regulated industries ranging from cybersecurity to aerospace, including WhiteFox Defense Technologies, a company that is shaping the future of drone airspace security. With a degree in engineering and as a member of the Forbes' 30 Under 30 list in 2019., Luke is currently leading NEXT’s efforts to introduce Plan A to the market.
In this interview, Luke shares invaluable lessons on fostering collaboration in a competitive space, understanding key stakeholders, and the art of raising capital. Whether you're an aspiring entrepreneur or simply curious about how innovation can drive societal change, this conversation offers key takeaways for all.
Before we dive into the discussion, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, if you'd much rather read, here's a link to the full interview with Luke Fox.
In this episode of Medsider Radio, we sat down with Dr. Krishan Ramdoo, the CEO and creative mind behind the Tympa platform, an all-in-one ear and hearing health assessment system that has gained global recognition.
Dr. Ramdoo is a celebrated international speaker, researcher, and educator with a keen focus on the intersection of medical science and technology. Some of the accolades Dr. Ramdoo and the Tympa team have received include the prestigious Royal Society of Medicine prize for innovation in ENT, the Rowena Ryan prize for research into ENT, and the Hartopp-Dixon ENT award.
In this interview, he talks about his journey toward becoming a technology innovator, starting as an ENT physician to eventually developing the Tympa platform. Dr. Ramdoo shares invaluable insights on the importance of patient-centric problem-solving, balancing external feedback with personal vision, and the power of tangible products in converting stakeholders to true believers in your solution.
Before we dive into the discussion, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's a link to the full interview with Dr. Ramdoo if you prefer to read it.
In this episode of Medsider Radio, we sat down with Allison London Brown, CEO of Luminelle, who has over 25 years of experience in the healthcare space and has been involved in nearly every aspect of product development for women's health.
From Fortune 50 companies like Johnson & Johnson and GE Healthcare to founding startups, Allison has seen it all. Now, as the CEO and co-founder of Luminelle, she's channeling her decades of knowledge into a revolutionary new device aiming to transform gynecological procedures.
In this interview, Allison shares insights on how to best understand your strengths and weaknesses, the potential pitfalls of 'one size fits all' regulatory strategies, and innovative methods to secure capital in a risk-averse economy.
Before we dive into the discussion, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's a link to the full interview with Allison if you prefer reading.
In this episode of Medsider Radio, we sat down with David Narrow, CEO of Sonavex, who has previously worked with multinational medical device companies on their commercialization and long-term business strategies as a healthcare consultant for Health Advances.
David earned his B.S. in Biomedical Engineering with Highest Distinction from the University of Rochester before receiving his Masters from Johns Hopkins University. He was named 30 Under 30 in Healthcare by Forbes in 2016 and 40 Under 40 by the Baltimore Business Journal in 2017.
In this interview with David, we talk about the art of perfecting product design, the strategies to adeptly navigate complex regulatory waters, and the nuances of capturing the trust and interest of venture capitalists.
Before we dive into the discussion, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's a link to the full interview with David if you prefer reading.
In this episode of Medsider Radio, we sat down with Shriram Raghunathan, a neuroengineering pioneer and CEO of Noctrix Health.
Shri has been leading his team in the development of innovative solutions to improve the lives of patients with neurological disorders like restless leg syndrome, aiming to level the playing field between medical devices and pharmaceuticals in patient care.
In this interview, Shri talks about how a mindset of exploration has driven his venture into the development of novel medical solutions within the challenging terrain of neurology. He also offers valuable insights on the critical importance of focusing on unmet needs, building a high-performance team, and navigating regulatory and capital-raising challenges.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's a link to the full interview with Shriram if you prefer reading.
In this episode of Medsider Radio, we sat down with Kate Rumrill, CEO of Ablative Solutions, a clinical-stage medical device startup specializing in transcatheter perivascular alcohol denervation for hypertension.
Kate is an accomplished leader with over three decades of comprehensive experience within the medtech and pharmaceutical industries. She brings a unique blend of expertise to the table, spanning roles from clinical affairs to executive management, with pivotal stints at prominent companies such as Eli Lilly and Covidien.
Her journey from being an aspiring neurosurgeon to leading a life sciences startup underscores the power of seizing unexpected opportunities. In this interview, Kate dives into her three-decade-long career and provides valuable lessons on the importance of thorough research, strategic clinical trial design, and effective reimbursement strategies.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's a link to the full interview with Kate if you prefer reading.
In this episode of Medsider Radio, we sat down with Lloyd Diamond, CEO of Pixium Vision a company that is developing a groundbreaking retinal implant system for patients suffering from advanced dry age-related macular degeneration (dry AMD).
Lloyd has a rich history of guiding medtech and biotech companies. His career spans decades, continents, and sectors, and he has been actively involved in both European and American markets. His experiences with large strategic firms and promising startups have equipped him with a unique entrepreneurial viewpoint.
In this interview, Lloyd shares practical lessons on building a lean and adaptable team, navigating the intricacies of regulatory processes, and succeeding at strategic fundraising. His insights, drawn from hands-on experience, provide actionable advice for startups making their way in the challenging medtech landscape.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a MedTech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's a link to the full interview with Lloyd if you prefer reading.
In this episode of Medsider Radio, we sat down with Craig Davis, CEO of NovaScan, a company revolutionizing cancer diagnostics with a low-cost, single-use device capable of real-time cancer detection and stratification.
Craig is a strategist, entrepreneur, and leader with a resume boasting a unique blend of business acumen, investment insight, and technical expertise.
In this interview, Craig unveils his journey from being a partner at LaSalle Investments to leading the charge in revolutionizing cancer diagnostics. He delves into the myriad of challenges entrepreneurs face, like fostering efficient early-stage development, designing clinical trials for rapid data collection, and mastering the art of fundraising in an ever-evolving financial landscape.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a MedTech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Brett Wingeier, co-founder and CTO of Magnus Medical, a privately held medical device company whose FDA-cleared SAINT™ Neuromodulation System aims to revolutionize mental health care.
Brett is a prominent figure in neuromodulation, leveraging his expertise in medicine, biology, and engineering to advance the arena within medtech. He was part of the pioneering team at NeuroPace and also co-founded Halo Neuroscience.
In this interview, Brett shares valuable insights into understanding the system you're working with, balancing consumer and provider perspectives, and ensuring cost-effectiveness for successful reimbursement.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a MedTech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Mara McFadden CEO of Endolumik, developers of an innovative fluorescence-guided esophagogastric calibration system.
Mara graduated as a mechanical engineer from the University of California, Berkeley. She further developed her business acumen during her MBA at Carnegie Mellon University and in various leadership positions with renowned healthcare companies such as Johnson & Johnson and Philips Healthcare.
Mara co-founded Endolumik, and in this interview, shares her philosophy of embracing imperfections and learning from your failures, why customer engagement and team culture are integral to business growth, and how the art of smart fundraising can lead to a thriving venture.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a MedTech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Joe Rafferty CEO of Vesteck, a developer of medical devices intended to treat patients diagnosed with aortic aneurysms.
Joe is a seasoned executive with a wealth of experience designing, building, and commercializing medical devices. In this conversation, Joe shares his storied journey in the medtech space, from his broad experiences within the cardiovascular arena to his current role leading Vesteck. Joe offers valuable insights on building a high-functioning in-house team, raising capital, and tips for ensuring your commercial launches are successful.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a MedTech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Rob Ball CEO of Shoulder Innovations, a leading orthopedic device company recognized for developing one of the most robust and stable glenoid platforms in the industry.
Rob, a graduate of Kettering University with a deep-rooted passion for engineering, has dedicated over two decades of his professional life to medical device technologies. Rob has over 30 issued or pending patents and has been instrumental in the growth of several organizations, most notably Tornier, where he drove the company’s revenue from $40 million to an impressive $300 million within a handful of years.
In this interview, Rob shares his unique journey from the automotive industry to the realm of orthopedics, emphasizing the importance of balancing technical problem-solving with commercial realities.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a MedTech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, we sat down with Tim Blair, CEO of ICHOR, an early-stage company developing a novel approach to thrombectomy in the peripheral vascular system.
With a rich, 30+ year career in the medtech industry, Tim Bhas held diverse roles spanning sales, marketing, and strategy development, both in multinationals and startups. In 2009, Tim brought his strategic vision to NAMSA, shaping it into one of the world's first Medical Research Organizations (MROs). Currently, as CEO and co-founder, Tim is leading ICHOR on its quest to transform thrombectomy in the peripheral vascular system.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a MedTech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
In this episode of Medsider Radio, I sat down with myself. Well, sort of.
This unique episode of Medsider flips the script, putting myself in the interviewee seat alongside my good friend, and temporary host, Brett Johnston. We discussed where founders should focus early on, guidance for taking the leap from your corporate position, and how to know which opportunities to pursue.
If you’re new to this show, here’s a little more about me:
I spent the last two decades in the medtech space, starting in medical device sales roles that ultimately led to startup leadership positions. During that time, I followed my curiosity through several career transitions while engaging in side projects along the way. I'm the founder of Medsider, Joovv, Crossfire Medical, and FastWave Medical. The latter two are spinouts from Big Sky Biomedical, a medtech accelerator that I also started with several other serial entrepreneurs.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Jennifer Ernst, CEO of Tivic Health.
Jennifer came to the medtech space after more than 20 years in the computing and electronics industries, serving in high-profile roles at Xerox PARC and Thin Film Electronics. In 2016, Jennifer founded direct-to-consumer medtech company Tivic Health and helped lead the development and commercialization of the company’s flagship device ClearUP.
In this interview, Jennifer shares how consumers can play a key role in boosting support and evidence for over-the-counter medical devices, and why she thinks direct-to-consumer business models will transform the medtech space.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Jennifer if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Dan Clark, President of Linear Health Sciences.
Dan Clark started his career in the private sector at Parker Hannifin, a Fortune 200 organization that he calls “the largest company you’ve never heard of.” After experiencing the medtech innovation cycle many times over, he was eager to innovate himself. In 2015, Dan teamed up with Dr. Ryan Dennis to start Linear Health Sciences, a medtech company that created the Orchid, a device designed to mitigate unwanted or accidental IV dislodgement.
In this interview, Dan explains when and how Linear raised capital, how it has navigated complex regulatory pathways, and why you need to be your own worst enemy as an innovator.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Dan if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Heather Underwood, CEO of EvoEndo.
Heather is a medical device and health technology entrepreneur with a highly interdisciplinary background at the intersection of computer science, global health, human-centered design, education, and international development.
In this interview, Heather elaborates on her unique approach to innovation in the medtech arena, how fundraising isn’t one-size-fits-all, and why regulatory clearance isn’t the end of the road.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Heather if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Yoav Kimchy, Founder and CTO of Check-Cap.
Yoav has more than 20 years of experience in the development and management of innovative medical device companies. In 2005, he founded Check-Cap, a clinical-stage medical diagnostics company that aims to change the colorectal cancer (CRC) screening landscape with its C-Scan ingestible capsule, tracing, and imaging system.
In this discussion, Yoav shares how early feedback from regulators can help streamline your development efforts, why you should shift your team as the company grows, and the importance of knowing when to lead and when to follow.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Yoav if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Bryce Klontz, President and CEO of New View Surgical.
With over 20 years of experience working in the surgical device space from Canada to Singapore, Bryce brings a tactical advantage to his role as the CEO of New View Surgical.
Under his leadership, New View Surgical has closed a successful Series B with a cumulative total of $14.5 million in investments and secured 510(k) clearance along the way. He previously worked as the VP of Commercial Strategy for Emerging Markets at Covidien in addition to leadership roles at several other startups.
In this discussion, Bryce shares insights from his decades of experience in the surgical devices space, from building relationships of trust with regulators and investors to working closely with practitioners to perfect product-market fit.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Bryce if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Eugene Malinskiy, CEO and Co-founder of Lazurite.
Eugene is a serial entrepreneur with expertise in the IT and medical fields. He also has hands-on experience as a medic and has worked in operating rooms throughout the country. He founded Lazurite, an innovative healthcare company focused on cutting-edge surgical and lighting technologies, in 2015. That same year, Eugene was selected as one of Forbes 30 Under 30 recipients in the manufacturing sector.
In this discussion, Eugene shares how planning out every step of ArthroFree’s regulatory strategy helped streamline the FDA clearance process, the importance of preparing for failure and being ready to solve problems, and why entrepreneurs should seek out input from investors at every step of the process.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Eugene if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Cody Simmons, CEO of DermaSensor.
Cody spent four years learning about business strategy and analytics at biotechnology giant Genentech before becoming CEO of DermaSensor in 2016, where he leads development and commercialization efforts for the company’s novel skin cancer detection tool. In 2018, he was included on the Forbes 30 Under 30 list in healthcare.
In this discussion, Cody shares why he thinks companies need to focus on regulatory and reimbursement alignment from the very beginning, the importance of finding ally investors, and how to build trust with potential partners in your network.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Cody if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Sina Habibi, CEO of Cognetivity.
Sina has a Ph.D. in engineering from the University of Cambridge, where he met his business partner Seyed-Mahdi Khaligh-Razavi. The two co-founded Cognetivity Neurosciences, which develops cognitive assessment tests for clinicians and patients to detect cognitive impairment, including dementia.
In this discussion, Sina shares the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Sina if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Olivier Delporte, CEO of Miracor Medical.
Olivier has more than 20 years of sales, marketing, and general management experience, mostly in the medical device industry. In 2016, he became the CEO of Miracor Medical, a medical device company based in Belgium. Under Olivier’s guidance, the company is advancing its flagship PiCSO treatment for severe myocardial infarction.
In this discussion, Olivier explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Olivier if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Laura Yecies, CEO of Bone Health Technologies.
Laura is a Silicon Valley veteran with more than three decades of experience at major tech companies and startups. She’s always had an interest in improving people’s health and wellness and was drawn to medtech startup Bone Health Technologies, which is developing a vibration belt intended to prevent osteoporosis.
In this discussion, Laura shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Laura if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Justin Zenanko and Greg Molnar, co-founders of SynerFuse.
Justin is a Certified Public Accountant who previously led fundraising efforts at Recombinetics and Greg is the former Director of Neuromodulation Research at Medtronic. In 2018, they joined forces to build SynerFuse, a clinical-stage startup developing an innovative therapy to relieve chronic back pain.
In this discussion, the two SynerFuse co-founders share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture.
Before we jump into the discussion, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Justin and Greg if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with David Neale, CEO and co-founder of Argá Medtech.
David has three decades of experience bringing medical goods, services, and devices to bear across a range of sectors and in multiple countries. In 2020, he launched Argá Medtech, a multinational company focused on developing new, more efficient ways to treat atrial fibrillation.
In this conversation, David explains how being a multinational company increased their chances of success, and why startups should incorporate economic outcomes into their clinical studies.
Before we jump into the discussion, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with David if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Justin Barad, Co-Founder and CEO of Osso VR.
Justin is an orthopedic surgeon with a passion for technology and a history of working in the video game industry. Using his experience and knowledge, he developed a virtual reality platform that can reform the way surgeons are trained and assessed.
In this conversation, Justin explains how he avoids being pulled in multiple directions with his technology, why it’s important to let potential customers get hands-on with your platform, and why tech can and should be fun — even in healthcare.
Before we jump into the discussion, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Justin if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with John Mastrototaro, CEO of Movano.
John has more than 30 years’ worth of experience in the medical device industry and was part of the MiniMed team that helped develop the world’s first ambulatory continuous glucose monitoring system and sensor-augmented insulin pump. John is now CEO and Director of Movano, a health technology company that makes smart, personalized devices that can provide vital health information to users.
In this conversation, we discuss how medtech companies can build a successful consumer-facing brand while developing products that meet the needs of payers and providers.
Before we jump into the discussion, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with John if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Jim Biggins, Founder and CEO of Access Vascular.
Before starting the company, Jim developed innovative products for companies like Boston Scientific, Ocular Therapeutix, and Medtronic. He then spent 18 months shadowing clinicians in real-life medical settings, which led to the creation of Access Vascular's novel biomaterial for vascular access devices aimed at reducing common patient complications.
In this conversation, Jim shares the importance of hearing directly from clinicians in the field, how to plan out a clinical research strategy, and the benefit of questioning assumptions when it comes to commercialization.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Jim if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Caroline Loew, President and CEO of Glympse Bio.
Caroline has been with Glympse Bio since 2018. Prior to that, she held executive roles at Merck and Bristol Myers Squibb, where she oversaw R&D. Caroline earned her bachelor’s and doctoral degrees at Imperial College, London.
In this discussion, Caroline shares her “early-and-often” approach to dealing with regulatory issues and outlines four things to consider ahead of conversations with potential investors.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Caroline if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Rosina Samadani, CEO of Oculogica.
Rosina Samadani initially joined Oculogica in an advisory role, supporting her neurosurgeon sister’s plan to develop EyeBOX, a diagnostic medtech device for concussions. In 2015, Rosina transitioned into her current role as President and CEO of the company. With a doctorate in biomedical engineering from MIT, Rosina has been involved with multiple startups. She also serves as a judge for Stanford’s StartX Accelerator, and MIT’s $100K Entrepreneurship Competition.
In this discussion, Rosina shares the importance of relationships in the regulatory and reimbursement processes, why first-time entrepreneurs shouldn’t be intimidated by complex procedures, and lessons learned from her experiences raising capital.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Rosina if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with John Murphy, President and CEO of Virtual Incision.
With a background in life sciences, aerospace, private equity, and venture capital, John co-founded Virtual Incision in 2006. The company makes miniature, portable robots that can be used to perform specific operations. The first iteration is designed for colon resections, with new variations planned for the future.
In this discussion, John shares tips on how to raise funds as an early-stage medical device company, planning a regulatory pathway that complements your product roadmap, and how to follow a dual-track approach to exiting (warning: it’s a lot of work).
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with John if you'd rather read it instead.
In this episode of Medsider Radio, we sat down with Robert Fenton, the founder and CEO of Qualio, a cloud-based all-in-one quality management system (QMS) for life sciences companies.
Prior to founding Qualio in 2012, Robert studied pharmacy for five years at the University College Cork, practiced as a community pharmacist, and spent time in quality and R&D roles at global pharmaceutical companies including Pfizer and LEO Pharma. Robert made the move to San Francisco in 2016 after bootstrapping Qualio in his home country of Ireland.
In this episode of Medsider, Robert shares his predictions for the life sciences industry in 2022. He also discusses how Qualio can support (and not hinder)medtech and healthtech companies as they move through the complex process of taking a product from conception to the market.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Robert if you'd rather read it instead.
In this episode of Medsider Radio, we’re sitting down with Holly Rockweiler, co-founder and CEO of Madorra.
Holly spent the early part of her career working as a research scientist for Boston Scientific. In 2013, she took a fellowship at Stanford University’s Byers Center for Biodesign, where she met her future business partner, Ryan Krone. Through the fellowship, Holly and Ryan developed Madorra, a non-hormonal medical device that treats vaginal dryness. As co-founder and CEO of Madorra, Holly’s on a mission to improve women’s health.
In this episode of Medsider, Holly discusses the importance of listening to your patients when developing medtech solutions, and why having a cause can be a valuable motivator. She also shares her most valuable learnings from participating in Stanford's Biodesign program.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Holly if you'd rather read it instead.
In this episode of Medsider Radio, we’re sitting down with Robert Kline, the Chairman of ThermoTek.
Robert left big pharma to start Medivance in 1998, which he later sold for $260 million in 2011. His next venture, ViroCyt, a spin-off from the University of Colorado, sold in 2016 for $16 million. Robert then joined startup Bolder Surgical in 2017, pivoted it, and sold the company in 2021 for $160 million. He’s now Chairman of ThermoTek.
In this episode of Medsider, Robert shares the lessons he learned from leading three medtech companies through successful acquisitions: never underestimate the importance and difficulty of fundraising, don’t assume everyone has the problem you want to solve, and don’t build your company around an exit.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Robert if you'd rather read it instead.
In this episode of Medsider Radio, we’re sitting down with Kevin Goodwin, the CEO and founder of EchoNous.
Kevin has already been part of a medical first. In 1998, he founded Sonosite, which released the first point-of-care ultrasound device (PoCUS) the following year. It was a classic startup story: Sonosite hit NASDAQ immediately after launching, with no product, no approval from the Food and Drug Administration (FDA), and no revenue.
Sonosite was acquired by Fujifilm in 2012, and Kevin left the company in 2014.
In 2015, Kevin co-founded EchoNous, to make a handheld PoCUS device that cost significantly less than the models used as the standard in hospitals. Even more ambitious, it would use AI and ML to not only deliver more accurate results, but to improve the detail and accuracy of those results over time. The company’s AI-powered Kosmos platform was approved by the FDA in 2020.
In this episode of Medsider, Kevin explains the pros and cons of public versus private investors, what happens when a competitor with an inferior product dominates the headlines, and why the toughest potential customers are the ones you should try to win over first.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Kevin if you'd rather read it instead.
In this episode of Medsider Radio, we’re sitting down with Sanjay Shrivastava. As the CEO and founder of Innova Vascular, and founder of the recently acquired BlackSwan Vascular, Sanjay’s deeply entrenched in the cardiovascular interventional device space.
Sanjay has worked for household names like Johnson & Johnson and Medtronic as well as small, early-stage startups. Throughout his career, he’s gained experience in various core functional areas of medical device companies, having led teams in R&D, marketing, and business development.
In this episode of Medsider, Sanjay explains the financial strategy he’s used in his two startups, gives advice on when (and how) to develop strategic partnerships, what questions to explore in the early stages of a medtech startup company, and the best timeline for a win-win exit strategy.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Sanjay if you'd rather read it instead.
In this episode of Medsider Radio, we’re sitting down with Marcus Gerhardt, who has started multiple companies, including an eCommerce platform and international consulting firm. In 2008, he co-founded Blackrock Neurotech, a pioneer in brain-computer interface (BCI) technology, and the world’s leading collaborative partner for developing approved medical devices at scale for neurological therapies. He currently serves as CEO and is on the company’s board.
In this episode of Medsider, Marcus explains why Blackrock’s business model works for medtech companies, how the approach gave the company an “in” with the neuroscience research community, and why medical device companies need to work with — and not against — regulatory bodies like the Food and Drug Administration (FDA).
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Marcus if you'd rather read it instead.
In this episode of Medsider Radio, we’re sitting down with Patricia Zilliox, wo has spent her entire career working in ophthalmology, including 30 years at American-Swiss medical company Alcon. In 2017, Patricia became CEO of Eyevensys, a biotech company in the clinical stage of making a drug delivery system to fight various eye diseases.
In this interview, Patricia gives advice for navigating the complicated world of regulatory affairs, the dos and don’ts of planning clinical trials, and why raising capital is the most frustrating part of her job.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Patricia if you'd rather read it instead.
In this episode of Medsider Radio, we caught up with the HealthQuest Capital Founder, Garheng Kong, who worked at GlaxoSmithKline, McKinsey and TherOx before transitioning into the world of healthcare investing with Intersouth Partners and Sofinnova.
Garheng’s resume is broad and deep. He has earned numerous degrees from two of the nation’s most prestigious universities — Stanford and Duke — and funded an equally impressive collection of healthcare companies throughout his career.
Garheng and his team see up to 1,000 investment opportunities in any given year. The experience has taught him how to assess which ones are right for the firm, and which he can afford to let go.
In this interview, Garheng shares keen insights for startups and innovators preparing to pursue funding, along with observations about how the healthcare industry has shifted thanks to the global COVID-19 pandemic.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Garheng if you'd rather read it instead.
In this episode of Medsider Radio, we’re talking with Lightpoint Medical CEO Graeme Smith, a medtech veteran with over 32 years of experience in the industry.
After joining Lightpoint earlier this year, Graeme was charged with commercializing its drop-in gamma probe, SENSEI, a revolutionary tool used in surgeries to non-invasively identify the presence of cancer.
In this Medsider interview, Graeme shares his tried and true strategies for successful commercial launches and how to introduce products using a global distribution model.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Graeme if you'd rather read it instead.
In this episode of Medsider Radio, we caught up with Steve Anderson, CEO of Preceptis Medical, and a serial medical device entrepreneur.
While serving as CEO of Acorn Cardiovascular, he and a neighbor came up with the idea of creating a device that could help doctors insert a tube in children’s ears in the doctor’s office instead of the operating room. They ended up starting Preceptis Medical in 2011, and in 2020, their Hummingbird device received clearance from the FDA.
In this discussion, Steve explains why your value proposition needs to be front of mind from the start, why having someone who’s been there and done it before can help you navigate the process of getting to market, and writing a study protocol that shows regulators exactly what they need to see.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Steve if you'd rather read it instead.
In this episode of Medsider Radio, we caught up with chemical engineer and serial entrepreneur Peter Vranes, the Co-Founder and CEO of Nutromics, an Australian medtech company that is developing a digitally connected wearable patch to track molecular targets.
Previously, Peter founded Biocore Technologies, which developed natural cosmeceutical skincare brands with distribution in 1,500 retailers throughout Australia. He had a successful exit in 2013.
In this fun discussion, Peter explains how he learned to embrace publicity as a necessary part of doing business, why getting your device approved goes beyond government regulatory bodies, and the reason he never stops raising money.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Peter if you'd rather read it instead.
In this episode of Medsider Radio, we’re talking with ReShape Lifesciences CEO Bart Bandy, who started out selling medical equipment door-to-door, then landed a spot in the first sales class for Ethicon Endo-Surgery. He ran the company’s global sales and managed the San Francisco division, before becoming Group Marketing Manager of Karl Storz Endoscopy.
In 1999, Bart was recruited to become COO of laparoscopic weight loss startup Inamed. He helped manage the company’s $3.5 billion acquisition by Allergan in 2006. Then in 2019, he became CEO and President of ReShape, which had just acquired the Lap-Band, previously owned by Inamed.
In this discussion, Bart explains how he writes and tests his presentations for maximum impact, the challenges and solutions of moving manufacturing from Costa Rica to the U.S., and why he wanted to add telemedicine to ReShape Lifesciences without moving away from the brand’s core mission.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Bart if you'd rather read it instead.
In this episode of Medsider Radio, we caught up with IONIQ Sciences CEO Jared Bauer, who has spent his career turning around struggling medtech companies. He acquired BurnFree Products in 2012, selling it four years later. In 2014, he became CEO of mobile diagnostics system ApolloDx. Shortly after, he became CEO of spin-off company Cibus Biotechnologies, which makes a handheld diagnostic system to test for infectious diseases.
In this conversation, Jared explains the two key factors he looks at when determining whether a medical device company is worth trying to turn around, why finding investors who really care about your mission is a strategic benefit, and why he hopes that IONIQ’s devices will one day have a place in your medicine cabinet.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Jared if you'd rather read it instead.
In this episode of Medsider Radio, we caught up with health economist, Nic Anderson, who spent seven years at Intermountain Healthcare on the payer side. He learned first-hand what evidence insurers need to convince them to cover a new medical device or healthcare technology.
After co-founding a biotech company, Nic turned his experience as a payer into an in-demand consultancy. He’s also served on payer advisory boards, and was an expert in residence at a digital health accelerator in Dubai. He now works as a health economist for Boston Scientific.
In this conversation, Nic explains why medtech companies, in particular, need to win over insurance payers, how investing early in a health economics and market access (HEMA) team will help you do that, and how to write a dossier a payer won’t want to throw out the window.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Nic if you'd rather read it instead.
In this episode of Medsider Radio, we caught up with Giovanni Lauricella and Aaron Green to discuss all things related to fundraising for early-stage medical device start-ups.
In this interview, we learn about the ins and outs of raising medtech capital, what investors want to see in a medical device start-up, and best practices for pitching potential partners.
But first, here’s a bit more about their backgrounds:
Giovanni Lauricella holds a Bachelor’s in Finance, a Master’s in Regulatory Affairs in Medical Devices, Biologics, and Pharmaceuticals, a Harvard University Certificate for Advanced Negotiation Strategy, and a Università Bocconi Certificate for Private Equity and Venture Capital. He has more than a decade of experience partnering with startups, SMEs, boards of directors, and investors on structuring technical and commercial teams from the C-level to individual contributors. Giovanni and his team have hired more than 7,000 employees for over 500 startups in more than 40 countries, and assisted in facilitating capital raises for startups that amount to more than $150 million.
Aaron Green has a PhD in computational chemistry from UCLA. In 2014, he became the first hire at Neural Analytics (now NovaSignal) where he held leadership roles spanning clinical, finance, sales, and marketing. Aaron currently runs U.S. operations for Labgnostic, a global interoperability platform for clinical laboratories. He co-founded MedTech Money with Giovanni Lauricella in 2020 and founded ExtractEx, a botanical extraction startup, in 2021.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Giovanni and Aaron if you'd rather read it instead.
In this episode of Medsider Radio, we’re talking with Dr. Asha Parekh, a biomedical engineer and the co-founder & CEO of FrontLine Medical Technologies, a Canadian medical device startup. FrontLine has developed a novel REBOA device that helps trauma patients survive in emergency situations. If you're not familiar, REBOA stands for Resuscitative Endovascular Balloon Occlusion of the Aorta.
In this discussion with Asha, we learn about her medtech journey from early-stage device prototypes to raising venture capital to navigating the global regulatory landscape.
But first, here’s a bit more on Asha’s background:
Asha has a PhD in biomedical engineering from Western University in Ontario. In 2015, she partnered with Dr. Adam Power, a practicing vascular surgeon, to co-found FrontLine, which makes the COBRA-OS device for trauma patients.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Asha if you'd rather read it instead.
In this episode of Medsider Radio, we're chatting with Mark Toland, a veteran medtech executive who is the CEO of MMI, a startup medical device company in the robotics space.
MMI stands for Medical Micro Instruments, and it’s an Italian company that’s developing a surgical robotic system capable of performing microsurgery on capillaries, small vessels, and other parts of the body existing robotic technology can’t reach.
We’re going to dig into the robotics arena and chat about things like growing medtech startups, raising venture capital, positioning for an acquisition, and keys to successful commercial launches.
First, here’s a bit more on Mark's background:
Before MMI, Mark was the CEO of Corindus, transforming the company into a leader in vascular robotics before it was acquired by Siemens for $1.1 billion in 2019. Prior to Corindus, Mark was at Boston Scientific for over 15 years, serving as Senior Vice President, where he built the company’s global solutions business and led all aspects of the U.S. commercial team’s cardiovascular businesses, representing approximately $4 billion in revenue.
He also serves on the Board of Directors for Cardiologs, a cardiovascular AI company, and Amplitude Vascular Systems, an intravascular lithotripsy company. He also serves as a partner and EIR at Biostar Capital, a healthcare-focused venture capital firm. Mark got his bachelor’s in business from the University of Louisville.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Mark if you'd rather read it instead.
In this episode of Medsider Radio, we're catching up with Derek Herrera, who has an incredible story to share. He’s a decorated Marine veteran who’s turned a major combat injury into a mission to help other patients with spinal injuries. Derek is the founder of UroDev, originally Spinal Singularity, as well as Habit Camera, the first low-cost, wireless camera purpose-built for skin inspection and telehealth.
UroDev is on the cusp of bringing its Intelliflow device to market, a product uniquely designed for spinal injury patients who have urology conditions like neurogenic bladder that require extensive catheter use.
Today, Derek and I are going to chat about his journey from the military to the medical device space, and get into what he’s learned about becoming a first-time entrepreneur with a big idea but not a lot of funding or experience.
First, here’s a bit more on Derek’s background:
He graduated from the United States Naval Academy and served as a Marine Infantry and Special Operations Officer for over eight years. In 2014, he was medically retired due to combat injuries, and left paralyzed from the waist down. Since this injury, Derek has earned an MBA from the UCLA Anderson School of Management and founded both UroDev and Habit Camera. He also serves as President of the Board for the Marine Raider Foundation.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Derek if you'd rather read it instead.
In this episode of Medsider Radio, we’re catching up with Bob Paulson, the CEO of VentureMed, a peripheral vascular medtech startup. Bob has over two decades of medical device executive experience, as the CEO of NxThera and Restore Medical, and in leadership roles at Endocardial Solutions, Advanced Bionics, and Medtronic. Bob’s excited multiple medtech startups, and today, he’s going to share his vast expertise, including capital fundraising tips, keys to early-stage medical device product development, and best practices when it comes to clinical evidence and insurance reimbursement.
But first, here’s a bit more on Bob’s background:
In addition to being CEO of VentureMed, he serves as a Director for Veran Medical Technologies and Spineology. Before he got started in medtech, he worked for General Mills, got an MBA from St. Thomas, and went to law school at Vanderbilt. Bob got involved with medical devices at Medtronic in the early 90s and later was CEO of NxThera, which commercialized benign prostate hyperplasia therapies before it was acquired by Boston Scientific. Bob is one of the most knowledgeable executives in the field, and I’m excited to get his take on the business landscape in today’s rapidly-changing healthcare environment.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Bob Paulson if you'd rather read it instead.
In this episode of Medsider Radio, we’re chatting with Dr. Scott Wolf, a prolific medical device entrepreneur and investor who founded Aerin Medical to bring non-surgical therapies to patients with common nasal airway problems.
Prior to founding Aerin Medical, Scott started Zeltiq Aesthetics, the maker of CoolSculpting. His other startups include Endogastric Solutions and Cardiac Dimensions, and he was a partner at Prospect Venture Partners as well as VP at Frazier Healthcare Ventures, both leading life science venture capital firms. Scott received his M.D. from George Washington University and his B.A. from the University of Pennsylvania.
You won’t find many people with more hands-on medtech experience than Dr. Scott Wolf, and today he’s going to share his expertise with the Medsider community. In this interview, we’ll discuss Aerin’s technology, break down the advantages of cash-pay versus insurance reimbursement, and get Scott’s advice for would-be founders hoping to turn a great idea into a real prototype.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Dr. Scott Wolf if you'd rather read it instead.
In this episode of Medsider Radio, we’re talking with Rohan Dixit, the Founder and CEO of Lief Therapeutics, which makes consumer- and clinical-grade wearable devices for mental health.
Rohan is a neuroscientist who started his career as a researcher with Stanford and Harvard. Rohan founded BrainBot, his first company, at age 23. He’s been the CEO of Lief since 2015.
Today, Rohan’s going to break down how Lief started, and we’ll get into product development, how he approaches clinical research, why they initially launched their device as an over-the-counter consumer product, and many other topics related to medtech startups.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Rohan Dixit if you'd rather read it instead.
In this episode of Medsider Radio, we’re talking with Nadim Yared, the CEO of CVRx, a pioneer in neuromodulation for cardiovascular diseases.
Nadim has been CEO for 15 years and led CVRx through some major pivots and incredible successes. Today, we’re going to discuss his journey with the company, including Nadim’s expertise on clinical trial strategy, startup funding, and working with FDA & CMS.
But first, here’s a bit more about Nadim Yared and his background:
Nadim holds two graduate degrees, and started his career with GE. After getting his MBA at INSEAD, he went on to run several business units for GE, then spent four years as the head of Medtronic’s Surgical Navigation division. Nadim was then recruited to take the helm at CVRx in 2006, and has been CEO ever since.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Nadim Yared if you'd rather read it instead.
In this episode of Medsider Radio, we’re talking with the CEO of Lungpacer Medical, Doug Evans. Lungpacer is developing a novel therapeutic solution that preserves the strength of the diaphragm muscle for critically-ill patients on mechanical ventilation.
Doug is also a board member of Intact Vascular, which was acquired by Philips, and the former COO of Kensey Nash. He’s a medtech veteran with decades of experience launching startups, developing products, working with payers & regulators, and commercializing novel technologies. Today, we’re going to discuss all these topics, and hear more about Lungpacer’s impressive technology.
But first, here’s a bit more about Doug Evans and his background:
Doug started his career at GE in business development, and later joined Kensey Nash when it was just a startup with fewer than ten employees. As COO, he led Kensey’s growth to over 400 employees, across the span of 20 years, before they were acquired by Royal DSM. After that, Doug began working with other startups like Intact Vascular and TELA Bio.
Doug holds a master's degree in electrical engineering and photonics from Penn, as well as an MBA. He knows the medtech startup landscape better than just about anyone, and we’re grateful he’s sharing his perspective with the Medsider community.
Before we jump into the conversation, I wanted to mention a few things:
If you’re into learning from proven medtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from medtech experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with Doug Evans if you'd rather read it instead.
We recently caught up with Renee Ryan, the CEO of Cala Health, a bioelectronic medicine company that’s focused on wearable neuromodulation therapies that deliver individualized peripheral nerve stimulation. Renee has 25 years of experience in healthcare as an executive and investor, and in this episode, she shares her expertise with the Medsider community.
Renee will discuss some common mistakes that medtech startups make, and talk about what she looks for as an investor in early-stage companies. She shares tips on navigating the regulatory waters and obtaining insurance coverage & reimbursement. Renee also gives us some key learnings from her time at Johnson & Johnson, and talks about what’s new at Cala Health, including their recent FDA breakthrough device designation.
But first, here’s a bit more on Renee’s background:
She has 25 years of experience in the healthcare space. Previously, Renee led the medical technology investments for Johnson & Johnson Innovation on the West Coast and Asia Pacific for 8 years. While at J&J, she made over 15 new investments, including the Series A for Cala Health. Prior to her time at J&J, she was a healthcare investment banker at RW Baird, Jefferies, and Goldman Sachs. Renee has a great eye for innovation, and we’re excited to welcome her to Medsider today.
Before we jump into the conversation, I wanted to mention a few things:
First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe.
Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.
I’ve never tried this before, so let me know what you think!
Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates.
Lastly, here's the link to the full interview if you'd rather read it instead.
We recently caught up with medtech start-up extraordinaire, Mike Wallace, who shares his insights and experiences with the Medsider community. Mike is the co-founder and CEO of DeVoro Medical, an early-stage medical device company focused on developing innovative devices for peripheral thrombectomy.
Mike says the initial idea or concept for a medtech company is just 5% of the journey. Medsider is all about shining light on that other 95%!
In this conversation with Mike, he’ll give tips to newcomers, including some mistakes entrepreneurs often make in the early stages of their companies. Mike explains how you can pivot when an idea doesn’t pan out, and he’ll give his expertise on seed-stage fundraising as well as navigating the regulatory waters. Plus, more on his current work with DeVoro, including how he started working on problems related to peripheral thrombectomy.
But first, a bit more on Mike’s medtech background:
Prior to co-founding DeVoro Medical, Mike served as Chief Technical Officer and VP of Operations for Silk Road Medical. Mike has spent most of his professional career working for medical device start-ups, some of which include Target Therapeutics (acquired by Boston Scientific), BARRX Medical (acquired by Covidien), and Baxano (acquired by Trans1). In addition, Mike has co-founded and exited three other start-ups: TW Medical and GW Medical Neuro (both acquired by Stryker Corp) and CardioProlific (acquired by Philips).
Mike graduated with a B.S. in Mechanical Engineering from the University of Delaware, holds a M.S. in Mechanical Engineering from the University of California, Davis, and is the co-inventor or primary inventor on over 130 issued U.S. patents.
Before we jump into the conversation, I wanted to mention a few things:
First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe.
Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.
I’ve never tried this before, so let me know what you think!
Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates.
Lastly, here's the link to the full interview if you'd rather read it instead.
In this episode of Medsider Radio, we’re catching up with Bruce Shook, the President & CEO of Vesper Medical. Bruce is a medical device executive with more than 30 years of experience, and today, he’s sharing his insights with the Medsider community!
In this conversation, we’ll discuss key aspects of running a medtech company, from the early design and fundraising stages through an eventual sale and exit. Bruce shares his expertise on raising start-up capital, designing and prototyping products, navigating the regulatory landscape, and managing reimbursement and coverage strategies.
But first, here’s a bit about Bruce Shook’s background:
Most recently, Bruce served as CEO of Intact Vascular, which sold to Philips. Prior to Intact Vascular and Vesper Medical, Bruce was co-founder, Director, President and CEO of Neuronetics, a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression.
Previously, he was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders. Bruce also served as President of Abiomed, where he obtained a PMA for the first ventricular assist device. Bruce also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.
Bruce holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management. He also earned a B.S. degree in Chemical Engineering from Penn State University.
Before we jump into the conversation, I wanted to mention a few things:
First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe.
Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.
I’ve never tried this before, so let me know what you think!
Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates.
Lastly, here's the link to the full interview if you'd rather read it instead.
In this episode of Medsider Radio, we’re talking with Mike Kujak, the President & CEO of Francis Medical.
Mike breaks down Francis’ innovative new water vapor technologies, and provides some advice about developing the alpha & beta versions of a medtech product. We’ll also discuss how to navigate the early-stage regulatory environment, and hear Mike’s views on how best to plan & execute a clinical research strategy.
Then we’ll discuss fundraising strategies and ask Mike what’s next for Francis Medical as the company plans for its second-generation development program.
But first, a bit more on Mike's background...
Most recently, Mike was the Chief Marketing Officer and Senior Vice President of International Markets for NxThera. Prior to that, he was the Vice President and General Manager of the Prostate Health business unit of American Medical Systems.
Mike received his MBA from the University of St. Thomas and has a Bachelor of Science degree in physics and chemistry from the University of South Dakota.
Before we jump into the conversation, I wanted to mention a few things:
First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe.
Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.
I’ve never tried this before, so let me know what you think!
Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates.
Lastly, here's the link to the full interview if you'd rather read it instead.
In this episode of Medsider Radio, we caught up with Sean Saint, the CEO of Companion Medical, which recently sold to Medtronic. Sean has more than 20 years of engineering experience in medical devices and various start-ups. Here are a few topics we covered in this interview:
- How Sean and his team at Companion Medical came up with the idea for the InPen.
- Sean's advice for raising money from medtech investors.
- Companion Medical's insurance and reimbursement strategy for the InPen.
There's definitely a lot more that we cover in this discussion, but before we jump in, I wanted to mention a few things:
First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe.
So here’s what’s different: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.
I’ve never tried this before, so let me know what you think!
Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates.
Lastly, here's the link to the full interview if you'd rather read it instead.
This interview brings us to the end of a throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.
On this particular episode, I chatted with Rich Ferrari, Managing Director of De Novo Ventures, and one of the most well-known VC’s in the medtech space. Here are some of the points we covered:
- Novel ways to fund early-stage medical device companies.
- The metrics that are most important when it comes to early-stage versus late-stage medtech investing.
- Why does the FDA “runway” seem to get longer and longer over time?
- How Rich identifies and validates whether an idea is truly disruptive.
Download the transcript here.
We're coming to the end of the throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.
In this discussion with Sheila Heyer, President of Heyer Regulatory Solutions and former VP of Global Regulatory Affairs at Boston Scientific, we learn where medical device companies are missing the mark when it comes to the FDA approval process. Here are some of the things we chatted about:
- The three most important steps you can take right now to get your medical device approved faster.
- Quality submissions and solid relationships: the importance of honing these two concepts in order to enhance your regulatory approval process.
- The key characteristics that great medtech regulatory professionals all have in common.
Check out the full interview here.
This interview is a continuation of a throwback mini-series that I’ve been releasing over the past few weeks with some of my favorite Medsider guests of all time.
One of which is Lisa Suennen, who was then a Managing Member of Psilos Group, a healthcare-focused venture capital firm with approximately $600 million under management. Although this discussion is several years old and the audio quality isn’t the best, the insights Lisa provides are timeless. Here are some of the thing we covered:
- What does Lisa think when the goal of physicians is to “dagger historical price lists."
- Why Lisa and her partners at the Psilos Group favor late-stage deals.
- Corporate venture capital arms: friend or foe?
- And if you’re an early-stage medical device company, what is the best way to get the attention of Lisa Suennen and her peers in the VC world?
See more...
This interview is a continuation of a throwback mini-series that I’ve been releasing over the past few weeks with some of my favorite Medsider guests of all time.
On this particular episode, I chatted with Randel Richner, a true expert when it comes to healthcare economics and reimbursement. At the time of this interview, she was with Neocure Group, a company she founded and later sold to Intralign.
Although this discussion is several years old and the audio quality isn’t ideal, the insights Randel provides are timeless. Here are some of the thing we covered:
- A case study of how Randel helped save a medical device company from severe reimbursement implications.
- Randel’s unique “orchestra score” philosophy and how it aids in streamlining reimbursement strategies.
- The importance of defining the difference between how hospitals get paid and how physicians get paid.
- And what Randel means by the statement “comparative effectiveness is a code word for cost-effectiveness”.
See more...
This interview is part of a throwback mini-series to several years ago when I chatted with Kevin Bitterman, who at the time, was with Polaris Venture Partners. He’s now a partner with Atlas Venture, but the lessons you can glean from this discussion still hold true. Namely:
- What medtech venture capitalists like to see in a startup and how these early-stage medical device companies can best position themselves for success.
- What requirements would make for an attractive IPO opportunity?
- What questions should medtech startups have already answered before approaching a potential buyer?
- And in terms of a potential exit, what is more, important for a medical device startup – clinical data or commercial traction?
See more...
This interview is part of a throwback mini-series to several years ago when I chatted with my good friend, Joe Hage. He’s the CEO of Medical Marcom and Chairman of the Medical Devices Group, a community of over 350,000 medical device members. In this entertaining interview, here are some of the things we talked about:
- How Joe, with a limited medical device industry background, helped Cardiac Science become a medtech marketing leader.
- Why Joe thinks search engine optimization (SEO) is among the most important elements for your marketing mix.
- How you can use editorials to demonstrate medical device industry leadership.
- And why sending prospects to your website homepage may not be the best idea.
See more...
This interview is a throwback to several years ago when I chatted with Dr. David Albert about his incredible journey in bringing the AliveCor ECG app to market. Here are a few things we covered:
- The amazing story of how AliveCor’s iPhone app helped save a man’s life while on an airplane!
- The roller coaster ride Dr. Albert experienced in his pursuits to develop the ECG app.
- Five key lessons you can learn from Dr. Albert’s experiences.
- And his timeliness advice for ambitious doers, which includes the following: believe in your ideas don’t be afraid to swim against the stream.
Click here to learn more.
On this episode of Medsider Radio, our guest is Travis Sessions, the Founder and Chief Executive Officer of Biomerics, a leading mid-market interventional device contract manufacturer. He's also a Managing Partner of Med Venture Holdings, a unique medtech growth equity investor. With over 20 years of business management experience, Travis has successfully built and grown multiple medical device technology companies during his career. He got his start professionally at Dow Chemical and has held management positions at Microsoft and Parker Hannifin Corporation. Travis has a B.S. in Chemical Engineering from Brigham Young University and a Master’s in Business Administration from the University of Michigan.
Interview Highlights with Travis Sessions:
- Macro trends within the medtech market, including Travis’ thoughts on the future.
- Key differences between contract manufacturers (CMs) and large original equipment manufacturers (OEMs).
- Critical things that OEMs should look for when identifying and working with CMs.
- The origin story of Med Venture Holdings.
- What Travis looks for when vetting early-stage medtech ideas.
- Critical functions that need to be in place for a medical device startup to be acquired.
- Travis’ favorite book, the mentor he most admires, and the advice he’d give to his 30-year-old self.
Learn more...
In this episode of Medsider Radio, our guest is Matthew Amsden, the Founder and CEO of ProofPilot, a platform designed to help people design, launch and participate in clinical trials.
ProofPilot’s mission statement revolves around making it incredibly easy to run scientifically-valid research studies. They’re dedicated to making research study participation accessible, interesting, and fun.
In this discussion with Matthew, we chatted about the importance and feasibility of virtual clinical trials, how they can potentially become a revenue driver, the origin story of ProofPilot, and why their hybrid model is so popular.
Interview Highlights with Matthew Amsden
- Who is Matthew Amsden and where did the idea for ProofPilot begin?
- The importance of letting early customers try product iterations.
- How clinical studies can become a revenue driver.
- Various types of clinical trials and how they’re conducted on the ProofPilot platform.
- Risky and costly approaches to traditional clinical studies.
- The synergy between data, compliance, and incentives.
- How a virtual, hybrid model can solve problems when it comes to traditional clinical trials.
- Matthew’s favorite business book, the mentor he most admires, and the advice he’d give to his 30-year-old-self.
See more...
Over the last 20 years, Dr. Tej Singh has served as the Founder and Chief of Vascular Surgery for three large, multidisciplinary vascular programs in Silicon Valley. He has vast experience with renal failure and vascular access procedures, and is acutely focused on his first company, Fist Assist Devices. Dr. Singh’s company is developing the first renal care wearable device for venous enlargement and dialysis enhancement.
In this episode, Dr. Singh and I talk about the primary challenge thatFist Assist Devices is trying to solve, the origin story for their first product, his approach to mapping out clinical trial strategies, and much more.
Interview Highlights with Dr. Tej Singh
- Who is Dr. Tej Singh and what is his background?
- What is Fist Assist Devices and what challenges are they trying to solve?
- The origin story for their first product and the critical inflection points for the company.
- How Dr. Singh evaluated the IP landscape for his first device.
- Dr. Singh’s approach to mapping out clinical trial strategies.
- How he navigated the insurance coverage and reimbursement landscape.
- His unique approach to strategic patience and why it’s crucial for medtech startups.
- Dr. Singh’s favorite book, the leader he most admires, and the advice he’d give to his 30-year-old self.
See more...
I recently sat down with Katherine Ward, Chief Commercial Officer and managing director for Healthy.io. She has worked in healthcare for 28 years — including 15 years with the UK National Health Service and 11 years with United Health Group where she was the Chief Executive with United Health UK and Chief Growth Officer with Optimum International. In this conversation, we cover what Healthy.io does for the broader healthcare community, lessons from the COVID-19 crisis, clinical-grade population health technology, decentralized remote diagnostic screening, and how their technology works with existing health systems.
Interview Highlights with Katherine Ward
- Who is Katherine and what is her background?
- What is Healthy.io and what challenges or problems do they solve for patients and clinicians?
- Why the time finally come for decentralized remote diagnostic screening, using urine testing as an example.
- Lessons on the importance of virtual testing from the COVID-19 crisis.
- How Healthy.io has approached the regulatory and reimbursement landscapes, including their clinical trial strategy.
- How their population health technology works together (with and within) existing healthcare systems.
- Katherine’s favorite genre of books, the leader she most admires, and the advice she’d give to her younger self.
See more...
In this episode of Medsider Radio, we downloaded with Jennifer Fried, the CEO and Co-Founder of ExplORer Surgical. Jennifer founded the company with Dr. Alex Langerman as an MBA student at the University of Chicago Booth School of Business, where she received her degree with honors in finance and entrepreneurship.
Previously, Jennifer was a Vice President at Park Lane Ventures, a healthcare-focused venture capital fund spun out of Essex Woodlands. Jennifer began her career as a consultant at Bain & Company in Chicago after graduating from Northwestern University.
With me on this episode is special guest host, Norbert Juist, who runs Sales Performance Resources, where he specializes in recruiting for medical device marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon.
Interview Highlights with Jennifer Fried
● How most medical device companies capture procedural data & workflow processes -- and why it’s completely outdated.
● The challenges medtech companies are facing when it comes to educational training & product development and why they’re considering platforms like ExplORer Surgical.
● Jennifer’s favorite business book, the business leader she most admires, and the advice she’d give to herself 5-10 years ago.
See more...
On this episode of Medsider Radio, I had the chance to sit down with Michael Tozzi, President and CEO of TAS Medical. Mike and his team are aiming to eliminate surgical mesh by converting hernia procedures to minimally invasive repairs.
Mike has over 20 years of commercial medical device experience and specializes in investor relations, sales & marketing readiness, and improving the execution of early-stage medical device companies..
Previous to TAS Medical, Mike served as Chief Commercial Officer at Carevoyance, where he and his team created groundbreaking analytics tools designed to help medical device companies better understand their markets and execute their commercial goals.
Prior to this, Mike helped to build Cardiovascular Systems, Inc. (or CSI) from the ground floor, taking the company from early stage to over $1.3 billion in market capitalization in just seven years. At CSI, Mike held various executive roles in sales and marketing.
Joining me on this episode is special guest host, Norbert Juist, who runs Sales Performance Resources, which specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon.
Interview Highlights with Mike Tozzi
- The origin story of TAS Medical and how Mike got involved.
- The strategies that TAS Medical followed to go from initial product concept to eventual commercialization.
- The regulatory and clinical paths that Mike and his team considered.
- How much the insurance coverage and reimbursement landscape factored into Mike’s early decision-making process.
- Mike’s approach to raising capital for CSI and TAS Medical.
- Common mistakes that early-stage medtech companies make and how to avoid them.
- Mike’s favorite book, the business leader he most admires, and the advice he’d give to his 30-year old self.
See more...
Joining Medsider Radio for this episode is Beverly Huss, President and CEO of Qool Therapeutics, a development-stage company working on a novel, non-invasive therapeutic hypothermia device for the preservation of tissue following catastrophic events like a heart attack, stroke, or traumatic brain injury.
Previously, Beverly was the CEO of Vibrynt, a start-up medical device company dedicated to creating minimally invasive therapies for patients suffering from morbid obesity. Prior to that, Beverly was the President of Guidant Endovascular Solutions (acquired by Abbott), a medical device company focused on the treatment of cardiovascular and peripheral vascular disease.
She holds an M.S. in technology management from Pepperdine University, as well as a B.S. in metallurgical engineering from the University of Illinois. Beverly also has a few patents to her credit in the cardiovascular and obesity medical device arenas.
With me on this episode is guest host, Norbert Juist, one of the most honest, genuine, and personable people I know. Norbert runs Sales Performance Resources, where he specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon.
Interview Highlights with Beverly Huss
- The origin story of Qool Therapeutics and how Beverly got involved with the company.
- The clinical trial strategy that Qool Therapeutics is following and the reasoning for it.
- Beverly’s strategic approach to making a medical device a reality, including the regulatory, clinical, and reimbursement paths that should be considered.
- Key learnings from Beverly’s time at Vibrynt.
- The “other R&R”: the importance of resilience and relentlessness when you are raising money for a company.
- How to get the attention of medical device venture capitalists.
- Critical lessons Beverly throughout her career at ACS and Guidant.
- Beverly’s favorite books and how they inspire resiliency.
- The business leaders and mentors that Beverly most admires.
- Advice Beverly would give to her 30-year old self.
See more...
I recently had the opportunity to interview Dan Rose, CEO of the French-based medtech company LimFlow. Founded in 2012, LimFlow transformed the peripheral vasculature space by providing a lifesaving option for end-stage critical limb-threatening ischemia (CLTI) patients facing amputation. LimFlow is designed to restore blood flow to the ischemic foot via deep vein arterialization, thereby preventing major amputation, resolving pain, and promoting wound healing.
Prior to assuming the role of CEO at LimFlow in August 2016, Dan had more than 16 years of leadership experience in the medical device and venture capital/startup sectors. Most recently, he was VP and General Manager EMEA for Direct Flow Medical, and VP of Commercial Operations and a Member of the Board at Sequana Medical, a Swiss medical device company.
Norbert Juist, an executive recruiter who specializes in medical device sales and marketing, also joined me for this interview with Dan Rose. Norbert brings a unique perspective to this discussion, having worked as a sales rep and consultant in medtech for nearly 20 years prior to transitioning to executive recruiting.
Here are a few of the topics we discuss in this episode:
- How LimFlow used a concept that’s been in existence since 1912 and transformed it into a modern therapy that multidisciplinary clinicians can reproduce.
- How Med Start played an instrumental role in the launch and ultimate success of LimFlow.
- Why it’s essential to find a physician champion willing to invest time and energy in your tech.
- Overcoming the challenges presented by an ever-evolving MDR landscape, both in the EU and US.
- Key factors you can’t ignore if you want to succeed as a first-time CEO.
- Why investing in independent market research is well worth the cost.
- Why the FDA Breakthrough Devices Program has been a game changer in the US.
See more...
After a brief hiatus from recording podcasts, it was a privilege to dust off the microphone and interview Kyle Frye. As U.S. president of SyntheticMR, Kyle is tasked with growing and expanding the brand and business in the U.S. for the Swedish-based company that is creating the future of quantitative MRI technology. Their innovative MRI software solutions support shorter exam times and deliver more information to clinicians, leading to improved diagnostic efficacies.
Prior to assuming this role in August 2019, Kyle was a Zone Vice President of Sales for Siemens, and also was in leadership positions at both niche and large medtech companies including Blue Belt Technologies (now Smith & Nephew), Verathon, and Brainlab. He also worked for BioMedix for three years, working his way up from a sales rep driving 4–5 hours a day to Western Area Sales Director, which required relocation from metro Cincinnati to the San Francisco Bay area. Kyle received a B.A. degree in political science and finance from Northern Kentucky University in 2004.
Norbert Juist, an executive recruiter who specializes in medical device sales and marketing, joined me as a special guest for this interview with Kyle. He brings a unique perspective to this discussion, having worked as a sales rep and consultant in pharma and medtech for nearly 20 years prior to transitioning to recruiting.
Here are a few of the key topics we discussed in this podcast:
- Why a competitive spirit and winning are important, but not the “be-all and end-all” to medical device success.
- Why communicating “the why” of career moves is key to landing new opportunities.
- How being flexible and willing to relocate can help advance your career, especially in the medtech space.
- The pros and cons of working for large vs. small companies.
- Kyle’s favorite business books, the importance of having a mentor, and the advice he would tell his 25-year-old self.
Check out the rest of the show notes here...
A few years ago, I had the privilege of sitting down and talking with serial medtech entrepreneur Paul Buckman, who at the time, was CEO of Conventus Orthopedics.
Prior to Conventus, Paul held CEO roles at SentreHEART, Pathway Medical Technologies (which sold to Bayer HealthCare), and Devax (which sold to Biosensors International). From 2004 through 2006, Buckman served as President of the Cardiology Division of St. Jude Medical.
Before joining St. Jude, he served as Chairman and CEO of ev3, a company that Buckman co-founded and was later acquired by Covidien for $2.5 billion dollars in 2010.
Paul has worked in the medical device industry for over 35 years, including 10 years at Scimed Life Systems and Boston Scientific where he held several executive positions before becoming President of the Cardiology Division at Boston Scientific in January of 2000. Buckman received a BA degree in business administration and an MBA degree from Western Michigan University.
Here are a few of the things we’re going to learn in this interview with Paul:
-
Of all the medtech startups that Paul’s been a part of, the two that are closest to his heart.
-
Two of the many key learnings that Paul recalls during his time helping to build Scimed.
-
When it comes to product development for medtech startups, why it’s critical to be ruthless about prioritization.
See more...
In late 2016, I was able to sit down with Kevin Sidow. At the time he was President & Chief Executive Officer for Moximed, and had been since 2008.
Prior to his time at Moximed, Kevin was President & CEO for St. Francis Medical Technologies, a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies was sold for $725 million to Kyphon, which was acquired by Medtronic later that same year.
Previously, Kevin was the Worldwide President of DePuy, where he supervised the global orthopedic, spine, trauma, and sports medicine businesses, with annual revenue responsibility of over $3 billion dollars. Kevin holds a B.S. in Accounting from West Virginia University.
Here are a few of the things we learned from Kevin:
-
How Kevin felt when Moximed’s first patient was treated with the Atlas System after 8+ years of research and development.
-
What makes the Atlas System different than other orthopedic knee implants.
-
How medtech professionals looking to take the next step in their career can utilize Kevin’s advice and learn from his meteoric rise to Worldwide President of DePuy.
See more...
In this two-part interview, I was lucky enough to sit down with Erica Rogers, CEO of Silk Road Medical. We first spoke a few years ago and then again much more recently to catch up on what had changed at Silk Road since our first conversation.
During our catch up, we discussed how Erica led her team at Silk Road through PMA approval, successful insurance coverage and reimbursement strategy, which led to a very rewarding public offering for Silk Road, opening at $20 a share. This resulted in the opportunity to continue the company’s goal, which is to change the standard of care in carotid artery disease with their TCAR procedure.
Much of our first conversation was about Erica’s career trajectory and how she was able to successfully, and gracefully, exit multiple medtech companies. Her lengthy career and insight as a medtech thought leader is just as interesting today as it was when we recorded our conversation.
Before leading Silk Road, Erica was the COO of Medicines360, a nonprofit pharmaceutical company developing drugs and devices for women. Erica was the founder and CEO of Allux Medical as well as the cofounder of Visiogen, which was acquired by Abbott Medical Optics in 2009.
Prior to that, Erica spent over 12 years at Boston Scientific in a variety of sales and marketing positions. She began her career in pharmaceutical sales after receiving a B.S. in Zoology from San Diego State University. Erica holds five issued and 15 pending US patents for medical devices in nanotechnology.
See more...
Daniel Hawkins is the President and CEO of Shockwave Medical. He began his career in marketing and business development roles for Advanced Cardiovascular Systems, otherwise known as ACS, which is now part of Abbott Vascular. Following ACS, he held senior roles in general management, marketing, and business development with a number of private and public...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Eric Stone cofounded Velano Vascular with Dr. Pitou Devgon, an internal medicine physician. Velano’s first device, PIVO, enables needle-free blood draws directly from peripheral IV catheters. Velano Vascular is backed by a series of well-respected investment firms, leading U.S. health systems, and dozens of health industry veterans. Before starting Velano Vascular, Stone most recently served...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Michael Branagan-Harris is the CEO of Device Access UK and has been involved in the marketing of medical devices to the National Health Service (NHS) for the last 27 years. Products he’s commercialized range from simple wound dressings to the introduction of the Lap Band for obesity, endovascular graft repair, endo laparoscopic surgery, and the...[read more]
Related Stories
- How Will These 2 Major Healthcare Changes Affect Medical Device Companies?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
- Social Media Best Practices for Marketing Medical Devices
Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Dr. Bob Smouse has over 20 years of experience in interventional radiology, endovascular surgery and clinical research. In addition to acting as CEO and CMO of BrightWater Medical and teaching at the University of Illinois College of Medicine, he provides interventional medical services to local hospitals through Central Illinois Radiology Associates. Dr. Smouse is a...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
More than a decade ago, AUM Cardiovascular founder Dr. Marie Johnson was a doctoral student when tragedy struck her and her family. Her husband, Rob, passed away suddenly at the age of 41. He had blockages in his coronary arteries including a ruptured plaque in the left anterior descending artery supplying a large part of...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Shaun Bagai is the CEO of RenovoRx. He has over 16 years of medtech experience across multiple functional areas like clinical research, sales, marketing, and market development. He was instrumental in developing the European market for renal denervation, which led to the acquisition of the first renal denervation company, Ardian, by Medtronic in 2011. Most...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Bill Facteau joined Earlens Corporation as Chairman, President, and CEO in November of 2013. Most recently, he was the Vice Chairman of ExploraMed, a medical device incubator based on the West Coast and an Entrepreneur in Residence at New Enterprise Associates. Previously, Bill was at Johnson & Johnson from early 2010 through early 2012 as...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Dr. John Simpson. Even if you’re a medical device newbie, you’ve probably heard of him. He’s credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA). This single idea created the field of interventional cardiology as we know it today. Over the course of his renowned medtech career...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Biz Stone, the co-founder of Twitter, has famously stated, “Timing, perseverance, and 10 years of trying will eventually make you look like an overnight success.” In the world of medtech startups, this is almost always the case. And it’s certainly true with UroLift, a device that came to life in the fall of 2004...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- How Will These 2 Major Healthcare Changes Affect Medical Device Companies?
Engaging with patients in a genuine and transparent way is tough. Really tough. It’s challenging for all healthcare stakeholders – payers, providers, and industry. From a medtech perspective, we often times get stuck in a certain mindset when trying to engage with patients. Whether it’s a continuous glucose monitor for diabetic patients or a new...[read more]
Related Stories
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
- Social Media Best Practices for Marketing Medical Devices
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
CMS has an objective to shift 50% of all reimbursement services from fee-for-service to alternative, value-based methods by 2018. And bundled payment models, according to Dr. Dan Mazanec, will be the principal driver of this transformative initiative. But the topic of value-based healthcare can be pretty confusing , right? Comprehensive Care for Joint Replacement. Medicare Access...[read more]
Related Stories
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
- Social Media Best Practices for Marketing Medical Devices
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
For as long as I can remember, at every company meeting I’ve ever been to, the topic of off-label promotion is always covered. Whether it was new-hire orientation, a national sales meeting, or some other large commercial event, the dissemination of off-label information was always presented as not only a fireable offense, but something that could get you...[read more]
Related Stories
- How Will These 2 Major Healthcare Changes Affect Medical Device Companies?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
- Social Media Best Practices for Marketing Medical Devices
Jack Dorsey received quite a bit of attention when he was recently announced as CEO of Twitter. Why? Because that made him CEO of 2 of the most rapidly-growing tech. companies in Silicon Valley at the same – Twitter and Square. Well, medtech’s version of Jack Dorsey might be Duke Rohlen. Duke led FoxHollow Technologies...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
I’ll be candid. This is an interview I’ve wanted to do for quite some time. During my time at Covidien, I considered myself fortunate to be involved with the acquisition of Sapheon, a startup company that manufactured a disruptive therapy for venous reflux. The more I learned about Sapheon through the diligence process (as well as...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
When most people think of the wearables space, devices like the Fitbit or the Apple Watch come to mind. But over the past few years, there’s been a lot of development with respect to wearable devices that were designed for the traditional healthcare market. Medtronic launched the SEEQ device. Although implantable, St. Jude commercialized the...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Because of diminishing margins, a lot of major medical device companies continue to add products to their sales bag in hopes of meeting top-line revenue goals. But selling the entire bag is challenging. When the bag gets too big, a typical sales force will usually focus only on products that generate the most revenue. So what...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Henry Ford is famous for stating, “If I had asked people what they wanted, I would have built a faster horse.” Although it’s arguable whether he ever uttered those words, the statement is still very powerful. And it’s one that Hugh Narciso has taken to heart. In fact, in the early days of BAROnova, when...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Sean Moore went from medical device sales rep to VP of Sales for one of the largest medtech companies in less than 10 years. Pretty impressive, right? Just like me, you might be thinking, “How did he do it? Killer sales results year after year? Right place at the right time?” In this interview with...[read more]
Related Stories
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
- Social Media Best Practices for Marketing Medical Devices
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
It’s safe to say that IDNs are important customers for the overwhelming majority of medical device companies. Therefore, it’s probably rational to assume that medtech companies do a good job of tracking the changing IDN landscape, right? Wrong. Based on the 2014 ZS Associates Commercial Operations Benchmark Study, only 56% of medtech companies track IDN...[read more]
Related Stories
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
- Social Media Best Practices for Marketing Medical Devices
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
According to a recent L.E.K. survey of hospital executives, 56% of the respondents haven taken steps to reduce medical device sales rep access to their facilities. In fact, the CEO of an Illinois hospital stated, “We’re constantly trying to limit the sales reps…We want to see what they’re selling before they get a hold of...[read more]
Related Stories
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
- Social Media Best Practices for Marketing Medical Devices
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
Information overload is an issue that all of us face. Finding a decent signal in the midst of a very noisy world is a difficult challenge. Few are able to master it on a consistent basis. And that includes doctors. Check out some of these stats: 100,000 scientific journals are now in circulation. 30,000 new...[read more]
Related Stories
- Social Media Best Practices for Marketing Medical Devices
- Can Nurep Solve the Inefficiency Problem in Medical Device Sales?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
What do Stryker, Biomet, Medtronic, and Boston Scientific all have in common? Yes, they all manufacture medical devices. But more specifically, all four of these medtech companies have implantable device divisions. And from 2005 – 2011, the implantable device segment has been the most consistent top performer relative to other categories including: in vitro diagnostics...[read more]
Related Stories
- Social Media Best Practices for Marketing Medical Devices
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Can Nurep Solve the Inefficiency Problem in Medical Device Sales?
Warren Buffet is often quoted as stating, “The best time to be greedy is when others are fearful.” But can this same concept apply to the medtech space? Can limited partners (the investors in a venture fund) be sold on the idea of bankrolling early stage medical device companies? In this interview with Mike Carusi...[read more]
Related Stories
- Why Intersect ENT is an Example of Hope for the Medtech Industry
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
How will healthcare reform affect care delivery and reimbursement? And what will the impact be for medical device companies? These are probably the 2 biggest questions that medtech companies need to answer in order to succeed in the future. Unfortunately, there aren’t solid answers at this point. But there are some people that can help...[read more]
Related Stories
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
- Social Media Best Practices for Marketing Medical Devices
- Why Intersect ENT is an Example of Hope for the Medtech Industry
Picture this. You’re a medical device sales rep covering a procedure in one part of your territory. But unexpectedly, you get a call from a physician needing case support on the other side of your geography. What do you do? There’s no way you can cover the case, right? The drive-time won’t allow you to...[read more]
Related Stories
- Social Media Best Practices for Marketing Medical Devices
- Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
The lean startup movement has become increasingly popular within the tech community after the release of Eric Ries’ book in 2011. Although I personally believe the lean startup methodology is brilliant, some aspects are difficult to apply to the medtech space. For example, it costs significantly less money to iterate on a software idea in...[read more]
Related Articles
- Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
- Social Media Best Practices for Marketing Medical Devices
The 2.3% medical device tax is burdensome. Regulatory timelines are long (and expensive). Reimbursement is not only decreasing, but also incredibly hard to obtain. Venture capitalists are losing interest in early stage medical device deals. Is it all downhill for medtech? There is no doubt the current healthcare environment is challenging. But certainly not impossible...[read more]
Related Articles
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Why Early Stage Medical Device Deals Aren’t as Bad as You May Think
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
Did you know the FDA recently issued a multi-million dollar contract to a private company that will be charged with monitoring social media? Yes, multi-million. Needless to say, that’s a significant amount of money. Although many would argue the FDA has not been very clear regarding its guidance towards social media, you can’t deny that...[read more]
Related Articles
- Can Nurep Solve the Inefficiency Problem in Medical Device Sales?
- Can Medical Device Companies Increase Sales and Reduce Costs at the Same Time?
- Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To
As the world of healthcare continues to change and evolve, hospitals and healthcare providers are facing a major dilemma. There will continue to be an increasing number of patients that need healthcare. But, the reimbursement for healthcare services will continue to decline. In other words, there will be more customers checking out, but less money...[read more]
Related Articles
- Social Media Best Practices for Marketing Medical Devices
- Are Medical Device Models the Key to Building a Lean Medtech Startup?
- Can Nurep Solve the Inefficiency Problem in Medical Device Sales?